A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease

Nina Vasavada, Chandan Saha, Rajiv Agarwal

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background. Torsemide has predictable absorption compared to furosemide. Thereby, torsemide results in more constant exposure to active drug. Our hypothesis was that this pharmacokinetic difference between these commonly used loop diuretics may translate into disparate antihypertensive responses in patients with chronic kidney disease (CKD). Methods. We conducted a randomized, double-blind, two-period, crossover trial to compare the pharmacodynamics of torsemide and furosemide, in 14 subjects with stage 2 or 3 CKD. We first performed an inpatient study, where after the subjects were brought into sodium balance on a 200 mEq per day diet, a single bioequivalent dose of oral loop diuretic was administered with an intervening washout period. Measurements of urinary electrolytes were made. Subjects then participated in an outpatient study, wherein they received daily therapy for 3 weeks with the loop diuretics in random order. Twenty four-hour ambulatory blood pressure monitoring was performed before and after each drug to assess the antihypertensive response. Results. In the inpatient phase, furosemide increased urinary sodium excretion from average (±SD) 199 ± 49 mEq/day to 357± 96 mEq/day and torsemide increased urinary sodium excretion from 213 ± 79 mEq/day to 398 ± 142 mEq/day. These differences between the diuretics were not significant, confirming bioequivalence. In the outpatient phase, furosemide reduced 24-hour ambulatory blood pressure from 147 ± 17/78 ± 11 mm Hg to 138 ± 21/74 ± 12 mm Hg (P = 0.021) and torsemide reduced it from 143 ± 18/75 ± 10 mm Hg to 133 ± 19/71 ± 10 mm Hg (P = 0.007). Although each diuretic was effective in reducing ambulatory blood pressure, the differences between diuretics were not statistically significant. Conclusion. Bioequivalent doses of torsemide and furosemide given in a randomized, double-blind design fail to demonstrate superiority of torsemide with respect to natriuresis or 24-hour ambulatory blood pressure control in subjects with stages 2 and 3 CKD.

Original languageEnglish (US)
Pages (from-to)632-640
Number of pages9
JournalKidney International
Volume64
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

torsemide
Sodium Potassium Chloride Symporter Inhibitors
Chronic Renal Insufficiency
Cross-Over Studies
Furosemide
Diuretics
Sodium
Blood Pressure
Antihypertensive Agents
Inpatients
Outpatients
Therapeutic Equivalency
Natriuresis
Ambulatory Blood Pressure Monitoring
Pharmaceutical Preparations
Electrolytes

Keywords

  • Chronic renal failure
  • Diuretics
  • Furosemide
  • Hypertension
  • Randomized controlled trial
  • Torsemide

ASJC Scopus subject areas

  • Nephrology

Cite this

A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. / Vasavada, Nina; Saha, Chandan; Agarwal, Rajiv.

In: Kidney International, Vol. 64, No. 2, 01.08.2003, p. 632-640.

Research output: Contribution to journalArticle

@article{0002041b9a0a4268b3ab60a62b04be89,
title = "A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease",
abstract = "Background. Torsemide has predictable absorption compared to furosemide. Thereby, torsemide results in more constant exposure to active drug. Our hypothesis was that this pharmacokinetic difference between these commonly used loop diuretics may translate into disparate antihypertensive responses in patients with chronic kidney disease (CKD). Methods. We conducted a randomized, double-blind, two-period, crossover trial to compare the pharmacodynamics of torsemide and furosemide, in 14 subjects with stage 2 or 3 CKD. We first performed an inpatient study, where after the subjects were brought into sodium balance on a 200 mEq per day diet, a single bioequivalent dose of oral loop diuretic was administered with an intervening washout period. Measurements of urinary electrolytes were made. Subjects then participated in an outpatient study, wherein they received daily therapy for 3 weeks with the loop diuretics in random order. Twenty four-hour ambulatory blood pressure monitoring was performed before and after each drug to assess the antihypertensive response. Results. In the inpatient phase, furosemide increased urinary sodium excretion from average (±SD) 199 ± 49 mEq/day to 357± 96 mEq/day and torsemide increased urinary sodium excretion from 213 ± 79 mEq/day to 398 ± 142 mEq/day. These differences between the diuretics were not significant, confirming bioequivalence. In the outpatient phase, furosemide reduced 24-hour ambulatory blood pressure from 147 ± 17/78 ± 11 mm Hg to 138 ± 21/74 ± 12 mm Hg (P = 0.021) and torsemide reduced it from 143 ± 18/75 ± 10 mm Hg to 133 ± 19/71 ± 10 mm Hg (P = 0.007). Although each diuretic was effective in reducing ambulatory blood pressure, the differences between diuretics were not statistically significant. Conclusion. Bioequivalent doses of torsemide and furosemide given in a randomized, double-blind design fail to demonstrate superiority of torsemide with respect to natriuresis or 24-hour ambulatory blood pressure control in subjects with stages 2 and 3 CKD.",
keywords = "Chronic renal failure, Diuretics, Furosemide, Hypertension, Randomized controlled trial, Torsemide",
author = "Nina Vasavada and Chandan Saha and Rajiv Agarwal",
year = "2003",
month = "8",
day = "1",
doi = "10.1046/j.1523-1755.2003.00124.x",
language = "English (US)",
volume = "64",
pages = "632--640",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease

AU - Vasavada, Nina

AU - Saha, Chandan

AU - Agarwal, Rajiv

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background. Torsemide has predictable absorption compared to furosemide. Thereby, torsemide results in more constant exposure to active drug. Our hypothesis was that this pharmacokinetic difference between these commonly used loop diuretics may translate into disparate antihypertensive responses in patients with chronic kidney disease (CKD). Methods. We conducted a randomized, double-blind, two-period, crossover trial to compare the pharmacodynamics of torsemide and furosemide, in 14 subjects with stage 2 or 3 CKD. We first performed an inpatient study, where after the subjects were brought into sodium balance on a 200 mEq per day diet, a single bioequivalent dose of oral loop diuretic was administered with an intervening washout period. Measurements of urinary electrolytes were made. Subjects then participated in an outpatient study, wherein they received daily therapy for 3 weeks with the loop diuretics in random order. Twenty four-hour ambulatory blood pressure monitoring was performed before and after each drug to assess the antihypertensive response. Results. In the inpatient phase, furosemide increased urinary sodium excretion from average (±SD) 199 ± 49 mEq/day to 357± 96 mEq/day and torsemide increased urinary sodium excretion from 213 ± 79 mEq/day to 398 ± 142 mEq/day. These differences between the diuretics were not significant, confirming bioequivalence. In the outpatient phase, furosemide reduced 24-hour ambulatory blood pressure from 147 ± 17/78 ± 11 mm Hg to 138 ± 21/74 ± 12 mm Hg (P = 0.021) and torsemide reduced it from 143 ± 18/75 ± 10 mm Hg to 133 ± 19/71 ± 10 mm Hg (P = 0.007). Although each diuretic was effective in reducing ambulatory blood pressure, the differences between diuretics were not statistically significant. Conclusion. Bioequivalent doses of torsemide and furosemide given in a randomized, double-blind design fail to demonstrate superiority of torsemide with respect to natriuresis or 24-hour ambulatory blood pressure control in subjects with stages 2 and 3 CKD.

AB - Background. Torsemide has predictable absorption compared to furosemide. Thereby, torsemide results in more constant exposure to active drug. Our hypothesis was that this pharmacokinetic difference between these commonly used loop diuretics may translate into disparate antihypertensive responses in patients with chronic kidney disease (CKD). Methods. We conducted a randomized, double-blind, two-period, crossover trial to compare the pharmacodynamics of torsemide and furosemide, in 14 subjects with stage 2 or 3 CKD. We first performed an inpatient study, where after the subjects were brought into sodium balance on a 200 mEq per day diet, a single bioequivalent dose of oral loop diuretic was administered with an intervening washout period. Measurements of urinary electrolytes were made. Subjects then participated in an outpatient study, wherein they received daily therapy for 3 weeks with the loop diuretics in random order. Twenty four-hour ambulatory blood pressure monitoring was performed before and after each drug to assess the antihypertensive response. Results. In the inpatient phase, furosemide increased urinary sodium excretion from average (±SD) 199 ± 49 mEq/day to 357± 96 mEq/day and torsemide increased urinary sodium excretion from 213 ± 79 mEq/day to 398 ± 142 mEq/day. These differences between the diuretics were not significant, confirming bioequivalence. In the outpatient phase, furosemide reduced 24-hour ambulatory blood pressure from 147 ± 17/78 ± 11 mm Hg to 138 ± 21/74 ± 12 mm Hg (P = 0.021) and torsemide reduced it from 143 ± 18/75 ± 10 mm Hg to 133 ± 19/71 ± 10 mm Hg (P = 0.007). Although each diuretic was effective in reducing ambulatory blood pressure, the differences between diuretics were not statistically significant. Conclusion. Bioequivalent doses of torsemide and furosemide given in a randomized, double-blind design fail to demonstrate superiority of torsemide with respect to natriuresis or 24-hour ambulatory blood pressure control in subjects with stages 2 and 3 CKD.

KW - Chronic renal failure

KW - Diuretics

KW - Furosemide

KW - Hypertension

KW - Randomized controlled trial

KW - Torsemide

UR - http://www.scopus.com/inward/record.url?scp=0038119499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038119499&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2003.00124.x

DO - 10.1046/j.1523-1755.2003.00124.x

M3 - Article

VL - 64

SP - 632

EP - 640

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -